With the emergence of the coronavirus disease 2019 (COVID-19) pandemic, concern has risen among physicians if treatment with biologic agents for psoriasis may result in a more severe disease course. 1,2 To date, only a limited number of cases have been published on the outcomes of COVID-19 infection in psoriatic patients under guselkumab, ustekinumab, adalimumab and secukinumab treatment, 3-5 yet no such case was reported on patients receiving risankizumab therapy. Here, we report on a 77-year-old male patient who has been suffering from chronic plaque psoriasis for 18 years, previously treated with several conventional and biologic drugs, including cyclosporine, methotrexate, infliximab, ustekinumab and secukinumab. The patient was switched to risankizumab 8 months ago as the last biologic agent, secukinumab, caused episodes of diarrhea. The patient's medical history included various diseases relevant to his psoriasis, such as rheumatoid arthritis, hypertension, acute myocardial infarction 20 years ago and chronic obstructive pulmonary disease (COPD) for 15 years.

No abstract